AU:LTP Stock Latest News
Company AnnouncementsLTR Pharma advances U.S. ROXUS launch and FDA pathway for SPONTAN4d agoLTP
Company AnnouncementsLTR Pharma outlines strategy and growth focus at 2026 AGM1w agoLTP
Company AnnouncementsLTR Pharma to Test Intranasal SPONTAN in Pulmonary Arterial Hypertension Trial1w agoLTP
Company AnnouncementsLTR Pharma marks 2,000 SPONTAN units as intranasal ED spray gains traction1w agoLTP- Company AnnouncementsLTR Pharma to Present Phase II Data and U.S. ROXUS Update in Investor Webinar3w agoLTP
Company AnnouncementsLTR Pharma Fulfils First U.S. ROXUS Prescriptions via Telehealth Channel3w agoLTPCompany AnnouncementsLTR Pharma to Showcase Clinical Data and Commercial Momentum in Upcoming Investor Webinar1M agoLTP
Company AnnouncementsLTR Pharma completes FDA pharmacokinetic dataset as SPONTAN shows rapid absorption and strong safety1M agoLTP
Company AnnouncementsLTR Pharma Sets October AGM as It Expands Intranasal Therapeutics Portfolio1M agoLTP
Company AnnouncementsLTR Pharma Seeks ASX Quotation for Additional Shares1M agoLTP- Company AnnouncementsLTR Pharma Seeks ASX Quotation for Additional Ordinary Shares1M agoLTP
Company AnnouncementsLTR Pharma outlines specialty therapy focus and restricts investor presentation use1M agoLTP
Company AnnouncementsLTR Pharma moves into oral testosterone with KYZATREX pilot deal2M agoLTPCompany AnnouncementsLTR Pharma Issues Unquoted Performance Rights Under Employee Incentive Scheme3M agoLTP
Company AnnouncementsLTR Pharma sets first U.S. telehealth route to market for ROXUS4M agoLTP- Company AnnouncementsLTR Pharma outlines limits and legal caveats in latest investor update6M agoLTP
Company AnnouncementsLTR Pharma Halts Trading Ahead of Interim SPONTAN Nasal Spray Trial Results6M agoLTP- Company AnnouncementsLTR Pharma advances SPONTAN Phase II study and U.S. ED spray strategy6M agoLTP
Company AnnouncementsLTR Pharma issues cautionary investor update on non-offer presentation7M agoLTP